BioAdvance News

Galleon Pharmaceuticals Reports Positive Results from Second Phase I Study of GAL-021 for Treatment of Respiratory Depression

By WebmasterSeptember 20, 2012November 1st, 2024No Comments

Galleon Pharmaceuticals Reports Positive Results from Second Phase I Study of GAL-021 for Treatment of Respiratory Depression
Read more here

Previous PostBioAdvance Expands Team to Support Portfolio Companies and New Investments
Next PostPhilly Inc: Small Businesses Solving Big Problems